Success Metrics

Clinical Success Rate
98.6%

Based on 70 completed trials

Completion Rate
99%(70/71)
Active Trials
86(45%)
Results Posted
61%(43 trials)
Terminated
1(1%)

Phase Distribution

Ph not_applicable
8
4%
Ph phase_1
29
15%
Ph phase_2
58
30%
Ph phase_3
43
22%
Ph phase_4
33
17%
Ph early_phase_1
4
2%

Phase Distribution

33

Early Stage

58

Mid Stage

76

Late Stage

Phase Distribution175 total trials
Early Phase 1First-in-human
4(2.3%)
Phase 1Safety & dosage
29(16.6%)
Phase 2Efficacy & side effects
58(33.1%)
Phase 3Large-scale testing
43(24.6%)
Phase 4Post-market surveillance
33(18.9%)
N/ANon-phased studies
8(4.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

94.6%

70 of 74 finished

Non-Completion Rate

5.4%

4 ended early

Currently Active

86

trials recruiting

Total Trials

193

all time

Status Distribution
Active(119)
Completed(70)
Terminated(4)

Detailed Status

Completed70
Recruiting63
Not yet recruiting31
Active, not recruiting23
Withdrawn3
Enrolling by invitation2

Development Timeline

Analytics

Development Status

Total Trials
193
Active
86
Success Rate
98.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (2.3%)
Phase 129 (16.6%)
Phase 258 (33.1%)
Phase 343 (24.6%)
Phase 433 (18.9%)
N/A8 (4.6%)

Trials by Status

withdrawn32%
completed7036%
not_yet_recruiting3116%
enrolling_by_invitation21%
recruiting6333%
terminated11%
active_not_recruiting2312%

Recent Activity

Clinical Trials (193)

Showing 20 of 193 trialsScroll for more
NCT07738276Phase 3

Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity

Not Yet Recruiting
NCT07573163Phase 2

Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

Recruiting
NCT07734870Phase 2

Tirzepatide for Treatment of CCCA

Not Yet Recruiting
NCT07734792Phase 2

Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial

Not Yet Recruiting
NCT07559500Phase 1

Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)

Recruiting
NCT07191873Phase 4

Tirzepatide in Idiopathic Intracranial Hypertension Trial

Not Yet Recruiting
NCT07349641Phase 2

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

Not Yet Recruiting
NCT07154719Phase 4

GLP-1R Actions on Muscle and the Skeleton

Active Not Recruiting
NCT07463846Phase 1

A Study to Evaluate ALN-2232 in Participants With Obesity

Recruiting
NCT07046819Phase 2

Tirzepatide in MetALD

Recruiting
NCT07257484Phase 4

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

Recruiting
NCT07715929Phase 4

Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients

Not Yet Recruiting
NCT06439277Phase 3

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

Recruiting
NCT06143956Phase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
NCT07707778Phase 4

Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV

Enrolling By Invitation
NCT06662383Phase 3

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

Active Not Recruiting
NCT06937086Phase 3

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Recruiting
NCT06651177Phase 2

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Recruiting
NCT06603571Phase 2

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Active Not Recruiting
NCT06534411Phase 3

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

Completed

Drug Details

Intervention Type
DRUG
Total Trials
193